Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.

Journal: JCO precision oncology
Published Date:

Abstract

PURPOSE: Evaluation of PD-L1 tumor proportion score (TPS) by pathologists has been very impactful but is limited by factors such as intraobserver/interobserver bias and intratumor heterogeneity. We developed an artificial intelligence (AI)-powered analyzer to assess TPS for the prediction of immune checkpoint inhibitor (ICI) response in advanced non-small cell lung cancer (NSCLC).

Authors

  • Hyojin Kim
    Center for Applied Scientific Computing, Lawrence Livermore National Laboratory, Livermore, CA, United States.
  • Seokhwi Kim
    Department of Pathology, Ajou University School of Medicine, Suwon, Korea (the Republic of).
  • Sangjoon Choi
    Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Changhee Park
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Seonwook Park
    Lunit, Seoul, Republic of Korea.
  • Sérgio Pereira
    CMEMS-UMinho Research Unit, University of Minho, Guimarães, Portugal; Centro Algoritmi, University of Minho, Braga, Portugal. Electronic address: id5692@alunos.uminho.pt.
  • Minuk Ma
    School of Electrical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea.
  • Donggeun Yoo
    Lunit Inc., Seoul, Republic of Korea.
  • Kyunghyun Paeng
    Lunit Inc., Seoul, South Korea.
  • Wonkyung Jung
    School of Nursing, University of Washington, Seattle, Washington, USA.
  • Sehhoon Park
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of).
  • Chan-Young Ock
    Lunit, Seoul, Korea (the Republic of) jeannes@stanford.edu ock.chanyoung@lunit.io.
  • Se-Hoon Lee
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of).
  • Yoon-La Choi
    Department of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Suwon, Korea (the Republic of).
  • Jin-Haeng Chung
    Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea (the Republic of).